# Spinchip Diagnostics AS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spinchip-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Oslo, Norway
- Website: www.spinchip.no
- Total disclosed funding: $2.6M
- Latest round: Series A (Apr 19, 2017)
- Investors on record: 3

## About

Spinchip Diagnostics AS, headquartered in Oslo, Norway, provides advanced point-of-care diagnostic solutions, enhancing efficiency in healthcare with rapid and reliable testing capabilities.Founded in 2012 in Oslo, Norway, Spinchip Diagnostics AS specializes in developing innovative diagnostic solutions. The company has completed five deals, with its latest funding round being a TRADE SALE, where it secured NOK 1.62 billion from bioMerieux on January 13, 2025. The acquisition aims to bolster Spinchip's capabilities in point-of-care testing, allowing for quick results comparable to laboratory standards.Spinchip Diagnostics AS focuses on the development and production of a groundbreaking all-in-one point-of-care (POC) platform designed for near patient testing. This platform supports rapid diagnostic testing, enhancing healthcare efficiency and patient well-being through features such as ease of use, accuracy, sensitivity, flexibility, affordability, and a quick turnaround from sampling to results. The primary users include healthcare professionals in hospitals and clinics across Europe and North America, addressing critical healthcare challenges with reliable and accessible diagnostic solutions.In 2023, Spinchip Diagnostics AS reported revenues of NOK 0, with an EBITDA loss of NOK 4,312,340.70. The company generates revenue through the direct sale of its diagnostic testing solutions to healthcare providers and institutions, ensuring that its products remain accessible while reflecting their value in enhancing diagnostic accuracy and patient outcomes.Spinchip Diagnostics AS is positioned for future growth following its acquisition by bioMerieux. The recent funding will enhance its point-of-care testing capabilities, enabling quicker findings that align with laboratory standards. The company aims to expand its product offerings and penetrate additional markets, with specific plans to enhance its presence in Europe and North America by leveraging its recent acquisition for improved distribution and operational capacity.

## Funding rounds

- Series A, Apr 19, 2017 — TRK Group
- Series A, Oct 1, 2012, $2.6M — SINTEF, Tronrud Engineering

## Investors

- SINTEF (https://capitalatlas.ai/funds/sintef) — Series A
- Tronrud Engineering — Series A
- TRK Group (https://capitalatlas.ai/funds/trk-group) — Series A